ArticleOpen forum infectious diseases2026
Human Metapneumovirus-associated Hospital Burden in Older Adults in Scotland: A Retrospective Analysis.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comparison of the Hospital Burden Associated with Respiratory Syncytial Virus and Human Metapneumovirus Across All Age Groups in Scotland: A Retrospective Analysis.Infectious diseases and therapy · 2026Article
- Hospitalisation Burden of Human Metapneumovirus and Respiratory Syncytial Virus in Adults by Age and Comorbidity Status in Scotland: A Retrospective Analysis.Infectious diseases and therapy · 2026Article
- Human Metapneumovirus-Associated Hospitalization Burden in Children Aged Under 5 Years in Scotland Between 2017 and 2023: a Retrospective Analysis.Open forum infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Human metapneumovirus (hMPV) is commonly associated with respiratory tract infections (RTIs) in older adults. Method: We estimated the annual hospital incidence of hMPV RTIs in older adults in Scotland over 6 seasons (2017-2023) using national hospital and laboratory data. Hospital incidence in Scottish health boards other than Lothian, where testing practices were uncertain, was extrapolated using Lothian's comprehensive laboratory data. We also assessed the severity and mortality outcomes of laboratory-confirmed hMPV episodes in older adults in Scotland. Additionally, we developed similar estimates for respiratory syncytial virus (RSV) and Influenza A for comparisons. Results: This analysis included 626 laboratory-confirmed hMPV hospitalizations. Only 28% of laboratory-confirmed hMPV episodes were clinically coded. The extrapolated hMPV hospital incidence ranged from 3.6/100 000 to 49.5/100 000 in adults aged ≥60 y in Scotland, and the extrapolated incidence was 1.3 to 3.8 times higher than the incidence of laboratory-confirmed data. The hospital incidence was higher in ≥75 y than in 60-74 y. hMPV incidence dropped substantially during the COVID-19 pandemic. The case fatality rates were higher in the ≥75 y compared with the 60-74 y, but ICU admissions were more common in the 60-74 y. The hospital incidence of RSV and Influenza A seemed higher than hMPV, but the 95% confidence intervals for severity and outcomes generally overlapped. Conclusions: hMPV RTIs pose a substantial hospital burden in older adults in Scotland. The differences between laboratory-confirmed and extrapolated estimates highlight the need for improved surveillance, diagnosis, and coding practices to develop robust burden estimates. The clinical severity of hMPV could be similar to RSV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.